Processa Pharmaceuticals has named Steven Cha, M.D. as Senior Vice President of Clinical Research. In this newly created position, Dr. Cha’s experience as an oncologist as well as in oncology drug development will be important additions to Processa. While at Puma Biotechnology, Dr. Cha was responsible for the global Phase 3 study in HER2+ breast cancer for the combination of neratinib and capecitabine.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCSA:
- Monster downgraded, Five Below upgraded: Wall Street’s top analyst calls
- Processa Pharmaceuticals initiated with a Buy at H.C. Wainwright
- Processa presents two abstracts at AACR 2024 including data on NGC-Cap trial
- Processa Pharmaceuticals’ Future in Jeopardy: A Dive into Its Financial Crisis and Industry Risks
- Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference